Jamie O'Hara

List of Publications by Year
in descending order

30 papers	407 citations	1162367 8 h-index	794141 19 g-index
30 all docs	30 docs citations	30 times ranked	460 citing authors

#	Article	IF	Citations
1	The lived experience of women with a bleeding disorder: AÂsystematic review. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12652.	1.0	8
2	The views of women with bleeding disorders: Results from the Cinderella study. Haemophilia, 2022, 28, 316-325.	1.0	5
3	New challenges for an expanding generation of older persons with haemophilia. The Journal of Haemophilia Practice, 2022, 9, 1-13.	0.2	0
4	Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. Journal of Medical Economics, 2022, 25, 386-392.	1.0	0
5	Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study. Orphanet Journal of Rare Diseases, 2022, 17, 148.	1.2	4
6	Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study. Orphanet Journal of Rare Diseases, 2022, 17, 150.	1.2	3
7	Examining patient and professional perspectives in the UK for gene therapy in haemophilia. Haemophilia, 2022, 28, 588-609.	1.0	5
8	Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia, 2021, 27, 113-119.	1.0	15
9	Evidence of a disability paradox in patientâ€reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252.	1.0	25
10	Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys. Orphanet Journal of Rare Diseases, 2021, 16, 143.	1.2	15
11	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal of Medical Economics, 2021, 24, 363-372.	1.0	8
12	Bleeding Data across Baseline FIX Expression Levels in People with Hemophilia B: An Analysis Using the 'Factor Expression Study'. Blood, 2021, 138, 592-592.	0.6	2
13	â€œYouâ€™re only a carrierâ€•â€“ women and the language of haemophilia. The Journal of Haemophilia Practice, 2021, 8, 128-132.	0.2	1
14	Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet Journal of Rare Diseases, 2021, 16, 521.	1.2	8
15	Achieving the unimaginable: Health equity in haemophilia. Haemophilia, 2020, 26, 17-24.	1.0	54
16	An Insight into the Impact of Hemophilia a on Daily Life According to Disease Severity: A Preliminary Analysis of the CHESS II Study. Blood, 2020, 136, 1-3.	0.6	2
17	The impact of factor infusion frequency on health-related quality of life in people with haemophilia. The Journal of Haemophilia Practice, 2020, 7, 102-109.	0.2	4
18	Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis. Blood, 2020, 136, 43-45.	0.6	0

#	Article	IF	Citations
19	Problem Joints and Their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia a: CHESS Paediatrics and CHESS II. Blood, 2020, 136, 33-34.	0.6	4
20	Evidence of a Hemophilia Employment Gap: Comparing Data from CHESS US+ and the 2019 Current Population Survey. Blood, 2020, 136, 26-27.	0.6	0
21	Examination and Validation of a Patient-Centric Joint Metric: "Problem Joint"; Empirical Evidence from the CHESS US Dataset. Blood, 2020, 136, 25-26.	0.6	2
22	Adherence and a Potential Trade-Off Currently Faced in Optimizing Hemophilia Treatment. Blood, 2020, 136, 40-41.	0.6	1
23	Economic burden of hemophilia B in the US: a systematic literature review. Journal of Drug Assessment, 2019, 8, 28-28.	1.1	6
24	Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes. Blood, 2019, 134, 2118-2118.	0.6	1
25	Longâ€term outcomes from prophylactic or episodic treatment of haemophilia A: A systematic review. Haemophilia, 2018, 24, e301-e311.	1.0	18
26	The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health and Quality of Life Outcomes, 2018, 16, 84.	1.0	62
27	The relationship between target joints and direct resource use in severe haemophilia. Health Economics Review, 2018, 8, 1.	0.8	39
28	Realâ€world comparative analysis of bleeding complications and healthâ€related quality of life in patients with haemophilia A and haemophilia B. Haemophilia, 2018, 24, e322-e327.	1.0	8
29	The cost of severe haemophilia in Europe: the CHESS study. Orphanet Journal of Rare Diseases, 2017, 12, 106.	1.2	105
30	A Descriptive Comparison of Disease Burden Between Hemophilia Patients with and without Inhibitors: Data from the CHESS Study. Blood, 2016, 128, 4756-4756.	0.6	2